Experience
Concert Pharmaceuticals, Inc.
Incyte Corp.
Finnegan successfully defended Incyte Corp. against institution of a post-grant review (PGR) proceeding filed against Incyte’s patent covering deuterated versions of the active ingredient in its FDA-approved Jakafi® product (ruxolitinib). The Patent Trial and Appeal Board (PTAB)’s decision wholly adopted many sections from Incyte’s preliminary response and agreed that petitioner had failed to establish any lack of enablement or written description support in the patent’s priority documents, thus concluding that the patent was not PGR eligible. Petitioner filed a rehearing request, which the PTAB also denied, resulting in a win for our client.
Concert Pharmaceuticals, Inc. v. Incyte Corp., PGR2017-00034, PTAB, Judges Paulraj, Sawert, Snedden
Finnegan secures a non-institution decision at the PTAB for Health Diagnostic Laboratory
Health Diagnostic Laboratory, Inc,
Securus Technologies, Inc. v. Global Tel*Link Corp.
Securus Technologies, Inc.
Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc.
Alzheon, Inc.
Finnegan goes three-for-three in IPR non-institution decisions for client inMusic
inMusic Brands, Inc.
Eli Lilly and Company v. Genentech, Inc.
Eli Lilly and Company
Actelion Pharmaceuticals v. ICOS Corp.
ICOS Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.